MCI

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Retrieved on: 
воскресенье, апреля 21, 2024
FDA, Radiation, Prospectus, MCI, CMO, Crohn's disease, News, Food, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

Lost Money on Anavex Life Sciences Corporation (AVXL)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

Retrieved on: 
четверг, апреля 18, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST, Cryptocurrency

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation (“Anavex Life Sciences” or the “Company”) (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation (“Anavex Life Sciences” or the “Company”) (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

Retrieved on: 
среда, апреля 17, 2024
MCI, LLP, News, Advertising, Radar, Avatar, Court, Clinical trial, Excellence, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Anavex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL

Retrieved on: 
среда, апреля 17, 2024
MCI, News, Radar, NEXT, Rett syndrome, Patient, Clinical trial, Fraud, Security (finance)

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm

Retrieved on: 
среда, апреля 17, 2024
FDA, Radiation, Prospectus, MCI, CMO, Sonder, Crohn's disease, News, Food, Annual report, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, Bank statement, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Retrieved on: 
суббота, апреля 13, 2024
FDA, Radiation, Prospectus, MCI, CMO, Crohn's disease, News, Food, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

Retrieved on: 
среда, мая 1, 2024
Research, Infectious Diseases, Clinical Trials, Health Technology, Philanthropy, General Health, Pharmaceutical, Health, Science, Oncology, Brain, MCI, Cancer, IP, Blood, Magnetic resonance, Immunotherapy, Pharmacotherapy, Speech, Digital, Therapy, Moa, Patient, Physician, Movement, Biomarker, Immune system, Mechanism, Sensory deprivation, Medical imaging

Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.

Key Points: 
  • Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.
  • The digital molecules are designed for hybrid drug experiences.
  • Remepy’s innovative approach creates a new market for hybrid medications, and a whole new world of data and IP assets for pharmaceutical companies.
  • Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments.

Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease

Retrieved on: 
вторник, апреля 30, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Amyloid, MCI, APOE4, Risk, Safety, Cognition, MD, Doctor of Philosophy, ADAS, Disease, MB, Week, Atrophy, Patient, Master of Science, Alzheimer's disease, CSF, Genotype, Biomarker, Neurotoxicity, Cerebrospinal fluid, Plasma, Pharmaceutical industry

Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.

Key Points: 
  • Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.
  • ALZ-801/valiltramiprosate is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid oligomers at the Phase 3 clinical dose.
  • “Given these encouraging results, we are compelled to extend the trial for an additional year, bringing the treatment period to four years for these patients.

Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting

Retrieved on: 
понедельник, апреля 29, 2024
Medical Devices, Health, Neurology, Research, Science, Biotechnology, Alzheimer's disease, Humanism, MCI, International Society, Literature, Patient, Caregiver, Cognito, Pharmacoeconomics, Therapy, Quality of life, Ageing, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.
  • The presented research is a targeted literature review of the clinical, humanistic, and economic burden of Alzheimer’s Disease (AD).
  • This surge underscores the pressing need for improved understanding and management of this debilitating neurological disease, given the current limitations in treatment options.
  • A targeted literature review was conducted to gain insights into the clinical, humanistic, and economic burden of mild-to-moderate AD, including mild cognitive impairment (MCI).

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation (AVXL) Shareholders

Retrieved on: 
четверг, апреля 11, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST, Cryptocurrency

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.